Patent intelligence · US
US 10106792
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
Patent details — US 10106792
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2018
- Expiration
- Oct 18, 2038
- Applicant
- INTEGRATED DNA TECHNOLOGIES, INC.
- Claims
- 2
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P1/04
Quick answer
US 10106792 (Methods and compositions for the specific inhibition of gene expression by double-stranded RNA) is held by INTEGRATED DNA TECHNOLOGIES, INC.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INTEGRATED DNA TECHNOLOGIES, INC.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P1/04, A61P1/16, A61P11/00
More from INTEGRATED DNA TECHNOLOGIES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12076377
Variant sulfatase enzymes with enhanced properties
granted -
US 11421021
Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
granted -
US 11260120
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
granted -
US 11186626
Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
granted -
US 11154614
Method for producing virus like particles
granted -
US 11135280
Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
granted -
US 11028153
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10653800
Oligonucleotide-based probes for detection of bacterial nucleases
granted
Frequently asked questions
What is US patent 10106792?
US 10106792 (Methods and compositions for the specific inhibition of gene expression by double-stranded RNA) is held by INTEGRATED DNA TECHNOLOGIES, INC.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10106792?
INTEGRATED DNA TECHNOLOGIES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 42 pharmaceutical patents for this assignee.
When does US 10106792 expire?
Our index shows an expiration date of Oct 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.